Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (311-320 of 362) with videos related to

Pageof 37
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 17, 2022
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape projectJan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2019
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF TrialMiguel-Angel Molina-Vila, Rolf A Stahel, Urania Dafni, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 17, 2022
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape projectJan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape projectLukas Bubendorf, Urania Dafni, Martin Schöbel, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2024
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape projectErnst-Jan M Speel, Urania Dafni, Erik Thunnissen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Pageof 37

Showing results (311-320 of 362) with videos related to

Sort By:
Pageof 37
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 17, 2022
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape projectJan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2019
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF TrialMiguel-Angel Molina-Vila, Rolf A Stahel, Urania Dafni, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 17, 2022
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape projectJan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape projectLukas Bubendorf, Urania Dafni, Martin Schöbel, et al.
The New England Journal of Medicine|September 29, 2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2024
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape projectErnst-Jan M Speel, Urania Dafni, Erik Thunnissen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Pageof 37